Abzena Expands Biotech Offerings with Innovative Cell Line Solutions
Innovative Solutions from Abzena
Abzena, a leader in integrated contract development and manufacturing for complex biologics, is releasing exciting developments in its AbZelectPRO™ cell line platform. This expansion showcases two next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression systems, enhancing both productivity and flexibility for biotech customers. These advancements represent a significant milestone in cell line development (CLD), enabling researchers to produce therapeutic proteins more efficiently.
The New GS Knockout Platforms
The newly introduced platforms, AbZelectPRO™-KO and AbZelectPRO™-KO+, are designed for versatility. They can function as standalone CLD solutions or as components of a fully integrated GMP service. This approach ensures that customers can choose a development strategy tailored to their specific project timelines, goals, and budgets, offering a simplified yet effective pathway to success.
Customer-Centric Approach
With insights from Campbell Bunce, the Chief Scientific Officer at Abzena, it's clear that the company is committed to forging strong relationships with its customers. Bunce emphasized that the addition of these GS knockout cell lines is an essential upgrade to the AbZelectPRO™ platform, setting a new benchmark for excellence in the industry. By focusing on robust solutions, Abzena is equipped to support the creation of therapeutic antibodies and tackle complex protein production challenges.
Enhancing Productivity with Advanced Technologies
These new GS knockout systems are powered by cutting-edge technologies licensed from Revvity. The GS knockout CHOSOURCE™ systems have been seamlessly integrated into the existing AbZelectPRO™ workflow. Complemented by ProteoNic Bioscience's innovative 2G UNic® vector technology, this combined effort significantly boosts productivity. Biopharma companies can now see quicker transitions from DNA to research cell banks (RCB), achieving high titers up to 10g/L in just 10 weeks.
Value Added by ProteoNic
Frank Pieper, CEO of ProteoNic, remarked on the synergy between their 2G UNic® vector technology and Abzena's platforms, highlighting the value this partnership brings to biopharma clients. The capacity to enhance productivity within CHOSOURCE™ and other cell lines solidifies its position as an essential resource for researchers aiming to streamline their operations.
Addressing Industry Needs
According to Bryan Kipp, Senior Vice President of Technology & Licensing at Revvity, the collaboration with Abzena is built upon the pursuit of excellence. They aim to mitigate ongoing challenges faced by customers in the biopharma industry while maximizing impact and productivity. The integration of Revvity's well-established CHOSOURCE™ cell lines into Abzena's platform reflects a commitment to providing comprehensive solutions that drive positive outcomes for researchers and patients alike.
About Abzena
Abzena stands as a prominent force in the biotech sector, providing end-to-end biopharmaceutical solutions. This encompasses everything from discovery to commercial launch, creating tailored strategies that streamline the development process for new therapies. With state-of-the-art facilities across various locations, Abzena's mission is to enable biotech partners to achieve their goals efficiently and effectively. The company is backed by Welsh, Carson, Anderson & Stowe, a leader in private equity investment.
About ProteoNic
ProteoNic is a pioneering biotechnology firm, based in The Netherlands, focusing on advanced methods for cell line generation and viral vector production. By leveraging the 2G UNic® vector technology, they are committed to enhancing protein production yields and efficiencies. Their collaborations span the entire biopharmaceutical industry, emphasizing a shared vision of accelerating the market introduction of groundbreaking biologics and therapies.
Frequently Asked Questions
What is the purpose of the new GS knockout platforms from Abzena?
The platforms are designed to enhance productivity and flexibility in cell line development for biopharma customers, allowing for faster transition and better yields.
How do the new GS knockout systems benefit researchers?
The systems provide a quick transition from DNA to research cell banks and support high-performing titers, enabling more efficient development timelines.
Who are the key partners in the development of these platforms?
Abzena collaborates with Revvity and ProteoNic to integrate advanced technologies that enhance the capabilities of their cell line development services.
What is Abzena's commitment to its customers?
Abzena focuses on building strong partnerships by offering innovative solutions and customizable services that address the specific needs within the drug development supply chain.
Where does Abzena operate its facilities?
Abzena has research, development, and GMP facilities in various locations, including California, Pennsylvania, and the UK, facilitating comprehensive support for its clients.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
